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Understanding mortality in bacteremic  
pneumococcal pneumonia
Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
Catia Cillóniz, Antoni Torres
Community-acquired pneumonia (CAP) caused 
by Streptococcus pneumoniae is one of the major 
causes of morbidity and mortality in children and 
the elderly (adults over 60 years of age) worldwide.
(1,2) Data from community-based studies show 
that the estimated overall annual incidence of 
pneumococcal bacteremia in the United States is 
15-30 cases per 100,000 population; the rate is 
higher for persons ≥ 65 years of age (50-83 cases 
per 100,000 population) and for children ≤ 2 years 
of age (160 cases per 100,000 population), with 
an overall case fatality rate ranging from 20% (in 
young adults) to 60% (in the elderly). Associated 
comorbidities also play an important role.(3) Among 
adults, 60-87% of all cases of pneumococcal 
bacteremia are attributed to pneumonia; among 
young children, the primary site of infection is 
frequently unidentified.(4,5)
Bacteremic pneumococcal pneumonia is a 
severe form of invasive pneumonia that constitutes 
a subgroup with features of its own. Approximately 
20% of patients with pneumococcal pneumonia 
develop bloodstream infection. Among adults with 
bacteremic pneumococcal pneumonia, mortality 
rates range from 10% to 30%.(6) Despite medical 
advances, including the wider availability of 
potent antimicrobial therapy, improved physician 
and nursing care, and even the establishment 
of ICUs, mortality in bacteremic pneumococcal 
pneumonia remains unacceptably high.(7) The 
current thinking is that mortality is higher among 
bacteremic cases than among nonbacteremic 
cases.(4) However, this is not borne out by data 
in the literature.
Since Austrian and Gold published their work 
in 1964,(8) a number of studies have compared 
CAP patients with and without pneumococcal 
bacteremia in terms of the clinical outcomes. 
Musher et al.(4) compared 52 cases of bacteremic 
pneumococcal CAP with 48 cases of nonbacteremic 
pneumococcal CAP and found that mortality 
within the first 7 days of hospitalization was 
significantly higher among the patients with 
bacteremic pneumococcal CAP. However, 
Marrie et al.(9) examined 56 subjects with 
bacteremic pneumococcal CAP and 394 subjects 
with nonbacteremic CAP (of any etiology). Those 
authors found that there were no significant 
differences between the two groups, in terms 
of overall mortality and length of hospital stay. 
More recently, Bordón et al.(10) provided data 
from the Community-Acquired Pneumonia 
Organization, confirming that pneumococcal 
bacteremia does not increase the risk of poor 
outcomes in patients with CAP.
In the current issue of the Brazilian Journal of 
Pulmonology, Palma et al.(11) present the results 
of a study regarding the impact that bacteremia 
has on outcomes among patients with CAP. The 
study cohort included 640 patients diagnosed 
with pneumococcal CAP over a 4-year period. 
The authors found that, in comparison with the 
patients who had nonbacteremic pneumococcal 
CAP, those with bacteremic pneumococcal 
CAP were older, presented more comorbidities 
(primarily cardiopathy and chronic renal failure), 
were more critically ill (according to their Acute 
Physiology and Chronic Health Evaluation II 
and pneumonia severity index scores), and were 
more often admitted to the ICU. However, in 
agreement with the findings of Marrie et al.,(9) 
there was no difference between the bacteremic 
and nonbacteremic groups in terms of all-cause 
mortality. The authors also demonstrated that 
bacteremia does not increase the length of the 
hospital stay in patients with pneumococcal 
CAP.(11)
Certain recognized factors might facilitate 
the understanding of mortality in bacteremic 
pneumococcal pneumonia: the time to the 
initiation of antibiotic therapy; the appropriateness 
of the initial therapy; and the treatment 
modality (monotherapy versus combination 
therapy). Garnacho-Montero et al.(12) evaluated 
125 cases of bacteremic pneumococcal CAP and 
found that the most important factor related 
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to mortality is the speed with which antibiotic 
therapy is initiated (ideally within the first 4 h 
after admission). However, this information is 
lacking from many studies, and it is therefore 
quite difficult to understand why invasive disease 
(bacteremia) does not influence mortality. The 
appropriateness of the initial antibiotic therapy 
is another factor associated with mortality 
in bacteremic pneumococcal pneumonia, as 
demonstrated by Lujan et al.(13) Data regarding 
this factor are also lacking from many studies. 
In addition, there is considerable retrospective 
evidence that combination therapy increases 
survival in bacteremic pneumonia.(14) Unfortunately, 
the study conducted by Palma et al.(11) provides 
no data on any of these factors.
An additional factor associated with mortality 
and morbidity in bacteremic pneumococcal CAP 
is the causative S. pneumoniae serotype. For 
example, Garcia-Vidal et al.(15) found that serotype 
3 is an independent risk factor for septic shock, 
which undoubtedly increases mortality. Again, 
Palma et al.(11) provided no data on this factor.
In conclusion, the results presented by 
Palma et al.(11) indicate that pneumococcal 
bacteremia is not an independent predictor of 
poor clinical outcomes in patients with CAP, despite 
the initial severity of patients with bacteremia. 
However, other important factors, such as the 
time to the initiation of antibiotic therapy and 
the appropriateness of the initial therapy, as 
well as the pneumococcal serotype, might play 
a crucial role and should be taken into account.
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